Riding a ‘Trojan horse’ against cancer

Project Information

TROJAN

Grant agreement ID: 956900

DOI

10.3030/956900

Project closed

EC signature date 20 July 2020

Start date 1 January 2021

End date 31 December 2022

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

No data

EU contribution

€ 150 000,00

Coordinated by

SZKOLA GLOWNA GOSPODARSTWA WIEJSKIEGO
Poland

Periodic Reporting for period 1 - TROJAN (Riding a ‘Trojan horse’ against cancer)

Reporting period: 2021-01-01 to 2022-12-31

Summary of the context and overall objectives of the project

Macrophages are continuously recruited into the tumor mass, even to the most hypoxic regions, and therefore represent a promising vehicle to deliver cancer therapeutics into the tumor. The pioneering research of our team demonstrated that macrophages are able to take up ferritins loaded with anti-cancer drugs, creating Macrophage-Drug Conjugates (MDCs). We have demonstrated that MDCs actively migrate to solid tumors, and we have proven that MDCs can be used as a ‘Trojan horse’ to efficiently deliver drugs directly to the cancer cells.

Now we aim to turn the MDC technology into a commercial and social value proposition by translating our findings to more reliable pre-clinical model for further clinical development. This project provide the proof of concept for the efficacy of our innovative MDC technology, and establish the viability, feasibility, commercialization and overall direction for our MDC technology.